A new study from The Hospital for Sick Children (SickKids) reveals the process underlying protein organization on cell ...

The University of Michigan, Johns Hopkins University, and the Hospital for Sick Children, where much of the initial research occurred, hold key patents on cystic fibrosis genetic sequences ...

A new inhalable gene therapy for cystic fibrosis (CF) has entered Phase I clinical trials, a major milestone on the journey towards seeing this treatment in the clinic. For this first phase ...

An inhaled gene therapy for cystic fibrosis developed by Boehringer Ingelheim is due to start clinical testing shortly, hoping to become a first-in-class treatment for the genetic disorder.

A recent retrospective study published in CHEST evaluated the effects of cystic fibrosis transmembrane conductance regulator ...

Cystic fibrosis (CF) is caused by defects in the CFTR gene, which causes a buildup of thick sticky mucus in the lungs and digestive system. It causes lung infections and gradually affects the ability ...

Porosome Therapeutics, Inc. announced the Orphan Drug Designation of its cystic fibrosis therapy by the Food and Drug Administration (FDA).

BI 3720931 is a first-in-class, inhaled lentiviral vector-based gene therapy that could potentially address unmet needs by inserting a functional copy of the CFTR gene in the DNA of airway ...

Cystic fibrosis (CF) is caused by defects in the CFTR gene, which causes a buildup of thick sticky mucus in the lungs and digestive system. It causes lung infections and gradually affects the ...

A new inhalable medicine, potentially improving lung disease in all cystic fibrosis patients, is in human trials across the UK and Europe (1 Trusted Source A Study to Test How Well BI ...